Marshall Wace LLP Trims Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Marshall Wace LLP reduced its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 25.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 843,144 shares of the company's stock after selling 285,409 shares during the period. Marshall Wace LLP owned about 1.46% of Rezolute worth $4,131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Rezolute by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after buying an additional 25,413 shares in the last quarter. Walleye Capital LLC acquired a new position in Rezolute during the fourth quarter worth about $2,408,000. Exome Asset Management LLC lifted its holdings in shares of Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company's stock valued at $1,707,000 after purchasing an additional 69,656 shares in the last quarter. State Street Corp grew its position in shares of Rezolute by 11.6% in the third quarter. State Street Corp now owns 125,472 shares of the company's stock valued at $609,000 after purchasing an additional 13,000 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock worth $316,000 after purchasing an additional 24,742 shares in the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Rezolute

In related news, CEO Nevan C. Elam bought 12,302 shares of the stock in a transaction dated Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the purchase, the chief executive officer now owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wladimir Hogenhuis acquired 10,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now directly owns 77,267 shares of the company's stock, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 39,060 shares of company stock valued at $130,694. Company insiders own 18.39% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on RZLT. Craig Hallum raised Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Guggenheim reiterated a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. JMP Securities upped their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Rezolute in a research note on Monday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Rezolute has an average rating of "Buy" and an average price target of $26.43.

Rezolute Stock Down 2.6 %

Shares of RZLT stock traded down $0.10 during trading hours on Wednesday, hitting $3.76. 457,877 shares of the company were exchanged, compared to its average volume of 596,806. Rezolute, Inc. has a 1 year low of $2.22 and a 1 year high of $6.19. The firm has a fifty day moving average of $3.31 and a 200 day moving average of $4.43. The firm has a market cap of $227.61 million, a PE ratio of -3.08 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.